Corporate Presentation on Wednesday, July 8th, 2015 at 9:30 AM ET
BOSTON – July 7, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced its Chief Executive Officer, Travis Wilson, will present a corporate overview and development update at Cantor Fitzgerald’s Inaugural Healthcare Conference in New York City. The presentation on Wednesday, July 8th at 9:30 AM ET will include the latest clinical results from Stealth’s Bendavia and Ocuvia, investigational drugs that target mitochondrial dysfunction to treat common and rare diseases.
Mr. Wilson will also participate in a 1 PM ET panel, “Emerging Trends in Ophthalmology: Innovative Products, FDA and the Evolving Landscape,” during the conference. Recently, Stealth’s Mitochondrial Science and Medicine Series highlighted its ophthalmology program, featuring promising findings from the ReVIEW study of Ocuvia in diabetic macular edema patients. The series further included presentations on rare mitochondrial optic neuropathies common to more than 20 orphan genetic diseases. Stealth is initiating a clinical study in inherited optic neuropathies with its ReSIGHT trial for Leber’s Hereditary Optic Neuropathy, a rare genetic mitochondrial disease causing sudden and permanent loss of vision.
“We are pleased to join this inaugural healthcare conference and its ophthalmology panel to discuss mitochondria’s role in eye diseases common and rare,” commented Mr. Wilson. “With the latest encouraging results from ReVIEW, Stealth continues to broaden its ophthalmology program, recruiting for the ReSIGHT study later this year, and initiating Ocuvia trials in patients with rare anterior segment diseases and corneal dystrophies, both underserved populations with few treatment options.”
For additional information on Bendavia or Ocuvia, please refer to Stealth’s website.
Mitochondria are the cell’s powerhouse, responsible for more than 90% of the energy our bodies need to sustain life and support growth. The energetics from mitochondria maintain healthy physiology and prevent disease. In many common and rare diseases, dysfunctional mitochondria are a key component of disease progression.
Stealth’s lead candidates, Bendavia and Ocuvia, are investigational drugs with the potential to modify disease through mitoprotection—the ability to preserve energetics and restore normal energy production in mitochondria, while decreasing oxidative stress. These clinical candidates are being developed for both common and rare diseases including inherited mitochondrial diseases, where there are no FDA-approved treatments. The underlying science of Bendavia and Ocuvia is supported by more than 100 independent, peer-reviewed publications and abstracts. These mitochondrial-targeted candidates represent a novel therapeutic approach to address a wide variety of diseases having unmet treatment needs.
Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. As an important and common element in a variety of serious, debilitating diseases, mitochondria—the cell’s energy source—offer a promising, and yet untapped, target to modify diseases with significant unmet treatment needs. Stealth’s clinical development program is focused along several core therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. By defining the broad potential of its mitochondrial platform and therapies, Stealth is leading mitochondrial medicine.
More information regarding Stealth and its pipeline is available at StealthBT.com.
Phone: (617) 520-7018
Phone: (212) 362-1200